Trial Profile
A double blind, placebo-controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention-deficit hyperactivity disorder.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Biomarker; Pharmacodynamics
- 27 Nov 2009 New trial record